Last updated: February 21, 2026
Case Overview
Supernus Pharmaceuticals, Inc. filed a patent infringement suit against Ajanta Pharma Limited in the United States District Court for the Southern District of New York. The case number is 3:21-cv-06964. Filed on September 15, 2021, the plaintiff alleges that Ajanta’s product infringes on patents held by Supernus related to formulations for neurological disorders.
Patent Claims and Alleged Infringement
Supernus asserts three patents: US Patent Nos. 9,555,115; 10,448,781; and 10,591,165. These patents encompass extended-release formulations of neuropsychiatric drugs, specifically targeting treatment for conditions such as epilepsy and bipolar disorder.
Supernus alleges Ajanta’s product, marketed as "Jalra," infringes these patents, particularly through the release mechanism and composition. Supernus’s claim hinges on the argument that Jalra’s formulation matches the patented release profile and component ratios.
Court Proceedings and Legal Issues
Core Legal Claims
- Patent infringement under 35 U.S.C. § 271.
- Invalidity defenses under §§ 102, 103, and 112.
- Possible declaratory judgment of non-infringement or invalidity by Ajanta.
Key Incidents and Filings
- Complaint (Sept 15, 2021): Details of infringement and patent claims.
- Answer and Counterclaims (Dec 10, 2021): Ajanta denies infringement, challenges patent validity based on obviousness.
- Preliminary Motions: Both parties filed motions to dismiss and for summary judgment.
- Expert Reports (Pending): Both sides submitted expert affidavits on formulation differences and patent validity.
Technological Dispute
At issue is the specific release mechanism claimed in the patents—whether Ajanta’s Jalra formulation meets all elements of the asserted claims, especially regarding the controlled-release properties.
Patent Validity and Prior Art
Ajanta challenges the patents’ validity under prior art references, including earlier extended-release formulations and combinations of known excipients. The validity analysis focuses on:
- Obviousness: Whether a person skilled in formulation development would find the patented compositions obvious.
- Novelty: Whether any prior art disclosures contain all claimed features.
Supernus counters that the combination of features produces unexpected results not obvious in the prior art.
Status of Litigation and Key Proceedings
As of April 2023, the case is in the pre-trial phase. Several dispositive motions have been filed, with motions to dismiss denied and summaries pending. The court has scheduled a Markman hearing (claim construction) for July 2023.
Case Significance and Industry Impact
This case exemplifies patent enforcement strategies in pharmaceutical formulations, especially extending patent scope through detailed claims on controlled-release mechanisms. The outcome could influence how formulation patents are challenged in the neuropsychiatric space and affect generic market entry timelines.
Financial and Market Implications
A ruling in favor of Supernus could lead to injunctions against Ajanta’s product, delaying or blocking sales until patent expiration or settlement. An invalidity finding could open the market for generics, affecting Supernus’s revenue from the patent family.
Key Dates
| Date |
Event |
| Sept 15, 2021 |
Complaint filed |
| Dec 10, 2021 |
Answer and counterclaims filed |
| July 2023 |
Claim construction hearing scheduled |
| Pending |
Summary judgment motions |
Legal and Patent Strategy Insights
- Patent owners should emphasize unexpected advantages in formulation claims.
- Challengers focus on prior art combinations, especially for obviousness challenges.
- Both sides prioritize expert testimony, which can strongly influence claim construction and validity outcomes.
Final Notes
Litigation remains pending, with the potential to shape patent enforcement practices for complex drug formulations. The case underscores the importance of detailed patent drafting and thorough prior art analysis in neuropsychiatric pharmaceutical patents.
Key Takeaways
- The case centers on patent infringement claims for controlled-release neuropsychiatric formulations.
- The dispute involves technical questions on release profiles and composition features.
- Validity challenges center around obviousness, with prior art references significantly scrutinized.
- The outcome will impact patent enforcement and generic entry timelines in the neuropsychiatric drug market.
- Court proceedings are in pre-trial, with key events scheduled for mid-2023.
FAQs
1. What is the primary legal issue in this case?
The primary issue is whether Ajanta's Jalra formulation infringes Supernus’s patents and whether those patents are valid under prior art challenges.
2. How could this case influence the pharmaceutical industry?
A ruling in favor of Supernus could reinforce the importance of detailed formulation patents, while a victory for Ajanta could weaken patent protections or validate broader generic manufacturing.
3. What are the key technical points being disputed?
Disputes focus on the release mechanism, composition ratios, and whether the claims encompass Ajanta’s product.
4. What is the status of the case?
The case is in pre-trial, with claim construction scheduled for July 2023 and summary judgment motions pending.
5. How do patent validity challenges impact market competition?
If challenged patents are invalidated, generic manufacturers can commercialize similar formulations sooner, reducing market share and pricing power for the patent holder.
References
[1] United States District Court for the Southern District of New York. Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, Case No. 3:21-cv-06964.
[2] Patent Office documentation, USPTO.
[3] Industry analysis reports on neuropsychiatric drug formulations.
